AU2013283487C1 - A phenyl triazole derivative and its use for modulating the GABAA receptor complex - Google Patents

A phenyl triazole derivative and its use for modulating the GABAA receptor complex Download PDF

Info

Publication number
AU2013283487C1
AU2013283487C1 AU2013283487A AU2013283487A AU2013283487C1 AU 2013283487 C1 AU2013283487 C1 AU 2013283487C1 AU 2013283487 A AU2013283487 A AU 2013283487A AU 2013283487 A AU2013283487 A AU 2013283487A AU 2013283487 C1 AU2013283487 C1 AU 2013283487C1
Authority
AU
Australia
Prior art keywords
pain
disorders
disorder
disease
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013283487A
Other languages
English (en)
Other versions
AU2013283487A1 (en
AU2013283487B2 (en
Inventor
Magnus Gustafsson
Carsten Jessen
Janus Schreiber LARSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saniona AS
Original Assignee
Saniona AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saniona AS filed Critical Saniona AS
Publication of AU2013283487A1 publication Critical patent/AU2013283487A1/en
Publication of AU2013283487B2 publication Critical patent/AU2013283487B2/en
Application granted granted Critical
Publication of AU2013283487C1 publication Critical patent/AU2013283487C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2013283487A 2012-06-26 2013-06-25 A phenyl triazole derivative and its use for modulating the GABAA receptor complex Ceased AU2013283487C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261664287P 2012-06-26 2012-06-26
US61/664,287 2012-06-26
DKPA201270368 2012-06-26
DKPA201270368 2012-06-26
PCT/EP2013/063193 WO2014001281A1 (en) 2012-06-26 2013-06-25 A phenyl triazole derivative and its use for modulating the gabaa receptor complex

Publications (3)

Publication Number Publication Date
AU2013283487A1 AU2013283487A1 (en) 2015-01-22
AU2013283487B2 AU2013283487B2 (en) 2017-05-25
AU2013283487C1 true AU2013283487C1 (en) 2018-01-18

Family

ID=49782299

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013283487A Ceased AU2013283487C1 (en) 2012-06-26 2013-06-25 A phenyl triazole derivative and its use for modulating the GABAA receptor complex

Country Status (10)

Country Link
US (2) US9206160B2 (enExample)
EP (1) EP2877463B1 (enExample)
JP (1) JP6224097B2 (enExample)
KR (1) KR20150033678A (enExample)
CN (1) CN104411699B (enExample)
AU (1) AU2013283487C1 (enExample)
CA (1) CA2876778A1 (enExample)
IL (1) IL236041A (enExample)
MX (1) MX357504B (enExample)
WO (1) WO2014001281A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10472324B2 (en) 2014-03-18 2019-11-12 Algiax Pharmaceuticals Gmbh 2-cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
EP3858965B1 (en) * 2020-01-28 2022-05-11 The Procter & Gamble Company Cleaning product
TWI901650B (zh) * 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔３，４－ｃ〕嗒衍生物
EP4126858B1 (en) 2020-03-26 2026-03-18 Richter Gedeon Nyrt. Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
CN116888115B (zh) * 2020-08-05 2026-03-20 萨尼奥纳有限责任公司 二氟甲基-吡啶-2-基三唑
CA3228655A1 (en) * 2021-08-12 2023-02-16 Shanghai SIMR Biotechnology Co., Ltd Substituted triazole derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof
WO2024023268A1 (en) 2022-07-29 2024-02-01 F. Hoffmann-La Roche Ag Characterisation of neurological dysfunction

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012062687A1 (en) * 2010-11-09 2012-05-18 F. Hoffmann-La Roche Ag Triazole derivatives and their use for neurological disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2314401A1 (en) * 1997-12-22 1999-07-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
CA2623043A1 (en) 2005-09-19 2007-04-12 F. Hoffman-La Roche Ag Isoxazolo derivatives as gaba a alpha5 inverse agonists
BRPI0617306A2 (pt) 2005-10-11 2011-07-19 Hoffmann La Roche derivados de isoxazol
BRPI0618383A2 (pt) 2005-11-09 2011-08-30 Hoffmann La Roche derivados de 3-aril-isoxazol-4-carbonil-benzofurano
BRPI0620146A2 (pt) 2005-12-23 2011-11-01 Hoffmann La Roche derivados de aril-isoxazolo-4-il-oxadiazol, processo para a preparação dos referidos derivados, medicamento que os contém e usos de um desses derivados
JP4864982B2 (ja) 2005-12-27 2012-02-01 エフ．ホフマン−ラ ロシュ アーゲー アリール−イソオキサゾール−４−イル−イミダゾ［１，５−ａ］ピリジン誘導体
KR101121372B1 (ko) 2005-12-27 2012-04-12 에프. 호프만-라 로슈 아게 아릴-이속사졸-4-일-이미다졸 유도체
CA2651857A1 (en) 2006-05-31 2007-12-06 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
BRPI0814718A2 (pt) 2007-06-22 2015-02-24 Hoffmann La Roche Derivados de isoxazol-imidazol
CA2706990C (en) 2007-12-04 2016-05-10 F. Hoffmann-La Roche Ag Isoxazolo-pyrazine derivatives
EP2227467B1 (en) 2007-12-04 2014-12-31 F. Hoffmann-La Roche AG Isoxazolo-pyridine derivatives
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US20100280019A1 (en) 2009-04-30 2010-11-04 Roland Jakob-Roetne Isoxazoles
ES2467701T3 (es) 2009-05-05 2014-06-12 F. Hoffmann-La Roche Ag Derivados de isoxazol-piridazina
AU2010244552A1 (en) 2009-05-05 2011-09-29 F. Hoffmann-La Roche Ag Isoxazole-pyrazole derivatives
SG175869A1 (en) 2009-05-05 2011-12-29 Hoffmann La Roche Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders
WO2010127976A1 (en) 2009-05-05 2010-11-11 F. Hoffmann-La Roche Ag Isoxazole-pyridine derivatives
AU2010244555A1 (en) 2009-05-07 2011-11-03 F. Hoffmann-La Roche Ag Isoxazole-pyridine derivatives as GABA modulators
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
NZ608592A (en) 2010-11-05 2015-08-28 Hoffmann La Roche Use of active pharmaceutical compounds for the treatment of central nervous system conditions
US8466181B2 (en) * 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012062687A1 (en) * 2010-11-09 2012-05-18 F. Hoffmann-La Roche Ag Triazole derivatives and their use for neurological disorders

Also Published As

Publication number Publication date
US9931329B2 (en) 2018-04-03
AU2013283487A1 (en) 2015-01-22
IL236041A0 (en) 2015-02-01
US20160067234A1 (en) 2016-03-10
JP6224097B2 (ja) 2017-11-01
IL236041A (en) 2016-09-29
MX357504B (es) 2018-07-12
MX2014014871A (es) 2015-06-17
EP2877463A1 (en) 2015-06-03
AU2013283487B2 (en) 2017-05-25
CN104411699A (zh) 2015-03-11
CN104411699B (zh) 2017-06-13
WO2014001281A1 (en) 2014-01-03
KR20150033678A (ko) 2015-04-01
JP2015521642A (ja) 2015-07-30
CA2876778A1 (en) 2014-01-03
US20150152085A1 (en) 2015-06-04
EP2877463B1 (en) 2018-11-07
US9206160B2 (en) 2015-12-08

Similar Documents

Publication Publication Date Title
AU2013283487B2 (en) A phenyl triazole derivative and its use for modulating the GABAA receptor complex
RU2194699C2 (ru) 1-фенил-бензимидазольные соединения, фармацевтическая композиция и способ лечения расстройства или заболевания, чувствительного к модуляции гамка-рецепторного комплекса центральной нервной системы
JP4211394B2 (ja) プロパン−１，３−ジオン誘導体
US9884848B2 (en) Phenyl triazole derivative and its use for modulating the GABAA receptor complex
JPH11501321A (ja) ベンズイミダゾール化合物、およびｇａｂａ▲下ａ▼レセプター複合体モジュレーターとしてのその使用
JP5155864B2 (ja) ５−ＨＴ２Ｃ受容体アゴニストとしての６−アリールアルキルアミノ−２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン
WO2014001279A1 (en) A phenyl triazole derivative and its use for modulating the gabaa receptor complex
CA2529445A1 (en) Melanocortin-4 receptor binding compounds and methods of use thereof
JPH11511734A (ja) ベンズイミダゾール化合物、およびｇａｂａ▲下ａ▼レセプター複合体のモジュレーターとしてのその使用
WO2014001278A1 (en) A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001280A1 (en) A phenyl triazole derivative and its use for modulating the gabaa receptor complex
JP2006522070A (ja) ベンズイミダゾール誘導体及びこれをｇａｂａａ受容体複合体をモジュレートするために使用する方法
US20080306044A1 (en) Spirobenzoazepanes as vasopressin antagonists
US7335777B2 (en) Benzimidazole derivatives and their use for modulating the GABAA receptor complex
JP2008535891A (ja) ベンゾイミダゾール誘導体及びｇａｂａａ受容体複合体修飾のためのそれらの使用
JP2012508726A (ja) ベンゾイミダゾール誘導体及びｇａｂａａレセプター複合体を調節するためのそれらの使用
JP2006522773A (ja) 新規ベンゾイミダゾール誘導体及び該化合物を含有する医薬組成物

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 AUG 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 AUG 2017

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired